Reference scaled approach for HVD [RSABE / ABEL]

posted by BE – 2009-03-19 13:30 (5902 d 04:05 ago) – Posting: # 3380
Views: 15,792

Dear HS,

❝ In the EU RSABE is not acceptable anyhow.


Please let me know when you state that RSABE approach is not accepted by EU, are you referring to any guideline. If such is the case, how you do recommend to conduct BE studies for HVD, especially to claim wider limits. I hope you agree that 2 way crossover is not the correct design the depict the innovator variability.

Best Regards,

BE


Edit: Quote restored. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
138 visitors (0 registered, 138 guests [including 6 identified bots]).
Forum time: 18:36 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5